title: Caffeine attenuates the renal vascular response to angiotensin II infusion.
abstract: Non-modulation has been proposed as an intermediate phenotype in human essential hypertension. The trait is characterized by blunted aldosterone and renal plasma flow responses to short-term angiotensin II (Ang II) infusion. Elevated tissue Ang II levels or decreased tissue adenosine levels could account for this decreased sensitivity to Ang II. In support of the latter possibility, endogenous adenosine has been shown to contribute to the renal vasoconstrictive response to Ang II in animals. We therefore tested the hypothesis that endogenous adenosine contributes to modulation of renal plasma flow in sodium-replete humans. We examined the effect of long-term administration of the adenosine receptor antagonist caffeine on baseline renal plasma flow and on the renal plasma flow response to short-term Ang II infusion in six salt-replete normotensive subjects in a single-blind, placebo-controlled study. para-Aminohippurate clearance was used to assess renal plasma flow. Ang II was infused in graded doses (0.3 to 3 ng/kg per minute) in the presence and absence of caffeine (250 mg PO TID for 7 days). Blood pressure, plasma renin activity, Ang II, electrolytes, and para-aminohippurate clearance were measured before and after each dose of Ang II. Caffeine did not alter either baseline blood pressure or the blood pressure response to Ang II but did increase baseline plasma renin activity from 0.72 +/- 0.09 to 1.42 +/- 0.26 ng angiotensin I/mL per hour (P = .01).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Vanderbilt University Medical Center, Division of Clinical Pharmacology, Nashville, TN.
authors.forename: N J
authors.initials: NJ
authors.lastname: Brown
authors.forename: D
authors.initials: D
authors.lastname: Ryder
authors.forename: J
authors.initials: J
authors.lastname: Nadeau
mesh_terms: D000311:Adrenal Glands / Q000187:drug effects / Q000378:metabolism; D000450:Aldosterone / Q000097:blood; D000704:Analysis of Variance; D000804:Angiotensin II / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D002110:Caffeine / Q000494:pharmacology*; D003404:Creatinine / Q000652:urine; D004305:Dose-Response Relationship, Drug; D004336:Drug Antagonism; D006801:Humans; D007262:Infusions, Intravenous; D008657:Metabolic Clearance Rate; D011188:Potassium / Q000652:urine; D012079:Renal Circulation / Q000187:drug effects*; D012083:Renin / Q000097:blood; D016037:Single-Blind Method; D012964:Sodium / Q000652:urine; D017673:Sodium Chloride, Dietary / Q000494:pharmacology; D010130:p-Aminohippuric Acid / Q000493:pharmacokinetics
chemical_list: D017673:Sodium Chloride, Dietary; D000804:Angiotensin II; D002110:Caffeine; D000450:Aldosterone; D012964:Sodium; D003404:Creatinine; D012083:Renin; D011188:Potassium; D010130:p-Aminohippuric Acid